Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

Overview of attention for article published in European Urology, January 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 2 news outlets
twitter: 55 X users

facebook: 1 Facebook page
guideline: 1 clinical guideline source

Readers on

mendeley: 56 Mendeley

So far, Altmetric has seen 58 X posts from 55 X users, with an upper bound of 248,611 followers.

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial @brian_rini @EUplatinum https://t.co/4ShGdr2FIw

ICYMI: Brief Correspondence in @EUplatinum by @WCMEnglanderIPM Clinical Director Dr. Cora N. Sternberg (@cnsternberg) and colleagues. #PrecisionMedicine https://t.co/eqnhsJ6hTZ

New2Trip: Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients w/ Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of Phase 3 PROTECT Trial https://t.co/fGGlRpsldO

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 54 additional X posts.